questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Utilisations thérapeutiques
Agents régulateurs de la reproduction
Fécondostimulants
Fécondostimulants : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Fécondostimulants : Questions médicales les plus fréquentes",
"headline": "Fécondostimulants : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Fécondostimulants : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-30",
"dateModified": "2025-02-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Fécondostimulants"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Agents régulateurs de la reproduction",
"url": "https://questionsmedicales.fr/mesh/D012102",
"about": {
"@type": "MedicalCondition",
"name": "Agents régulateurs de la reproduction",
"code": {
"@type": "MedicalCode",
"code": "D012102",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.705"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Fécondostimulants féminins",
"alternateName": "Fertility Agents, Female",
"url": "https://questionsmedicales.fr/mesh/D005300",
"about": {
"@type": "MedicalCondition",
"name": "Fécondostimulants féminins",
"code": {
"@type": "MedicalCode",
"code": "D005300",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.705.552.344"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Fécondostimulants masculins",
"alternateName": "Fertility Agents, Male",
"url": "https://questionsmedicales.fr/mesh/D005303",
"about": {
"@type": "MedicalCondition",
"name": "Fécondostimulants masculins",
"code": {
"@type": "MedicalCode",
"code": "D005303",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.705.552.510"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Fécondostimulants",
"alternateName": "Fertility Agents",
"code": {
"@type": "MedicalCode",
"code": "D005299",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "N Chabbert-Buffet",
"url": "https://questionsmedicales.fr/author/N%20Chabbert-Buffet",
"affiliation": {
"@type": "Organization",
"name": "Centre de fertilité Tenon, hôpital Tenon, Sorbonne université, AP-HP, Paris, France. Electronic address: nathalie.chabbert-buffet@aphp.fr."
}
},
{
"@type": "Person",
"name": "N Sermondade",
"url": "https://questionsmedicales.fr/author/N%20Sermondade",
"affiliation": {
"@type": "Organization",
"name": "Centre de fertilité Tenon, hôpital Tenon, Sorbonne université, AP-HP, Paris, France."
}
},
{
"@type": "Person",
"name": "E Moreau",
"url": "https://questionsmedicales.fr/author/E%20Moreau",
"affiliation": {
"@type": "Organization",
"name": "Centre de fertilité Tenon, hôpital Tenon, Sorbonne université, AP-HP, Paris, France."
}
},
{
"@type": "Person",
"name": "S Cristofari",
"url": "https://questionsmedicales.fr/author/S%20Cristofari",
"affiliation": {
"@type": "Organization",
"name": "Centre de fertilité Tenon, hôpital Tenon, Sorbonne université, AP-HP, Paris, France."
}
},
{
"@type": "Person",
"name": "N Johnson",
"url": "https://questionsmedicales.fr/author/N%20Johnson",
"affiliation": {
"@type": "Organization",
"name": "Centre de fertilité Tenon, hôpital Tenon, Sorbonne université, AP-HP, Paris, France."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis.",
"datePublished": "2024-10-31",
"url": "https://questionsmedicales.fr/article/39482761",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13075-024-03418-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.",
"datePublished": "2023-06-15",
"url": "https://questionsmedicales.fr/article/37098795",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/art.42510"
}
},
{
"@type": "ScholarlyArticle",
"name": "A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis.",
"datePublished": "2023-05-15",
"url": "https://questionsmedicales.fr/article/36787101",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/art.42477"
}
},
{
"@type": "ScholarlyArticle",
"name": "Disturbed Complement Receptor Expression Pattern of B Cells Is Enhanced by Toll-like Receptor CD180 Ligation in Diffuse Cutaneous Systemic Sclerosis.",
"datePublished": "2024-08-26",
"url": "https://questionsmedicales.fr/article/39273179",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms25179230"
}
},
{
"@type": "ScholarlyArticle",
"name": "Purtscher-Like Retinopathy Induced by Diffuse Cutaneous Systemic Scleroderma.",
"datePublished": "2023-11-09",
"url": "https://questionsmedicales.fr/article/37950491",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1093/qjmed/hcad255"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Utilisations thérapeutiques",
"item": "https://questionsmedicales.fr/mesh/D045506"
},
{
"@type": "ListItem",
"position": 5,
"name": "Agents régulateurs de la reproduction",
"item": "https://questionsmedicales.fr/mesh/D012102"
},
{
"@type": "ListItem",
"position": 6,
"name": "Fécondostimulants",
"item": "https://questionsmedicales.fr/mesh/D005299"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Fécondostimulants - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Fécondostimulants",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Fécondostimulants",
"description": "Comment diagnostiquer l'infertilité ?\nQuels tests pour évaluer la réserve ovarienne ?\nQuand consulter un spécialiste de la fertilité ?\nQuels signes indiquent un problème d'ovulation ?\nComment évaluer la qualité du sperme ?",
"url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Scleroderma,+Diffuse&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Fécondostimulants",
"description": "Quels symptômes d'infertilité chez la femme ?\nQuels signes d'infertilité chez l'homme ?\nComment reconnaître un déséquilibre hormonal ?\nQuels symptômes d'ovulation irrégulière ?\nQuels symptômes d'une maladie des ovaires ?",
"url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Scleroderma,+Diffuse&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Fécondostimulants",
"description": "Comment prévenir l'infertilité ?\nQuel rôle de l'alimentation sur la fertilité ?\nComment le stress affecte-t-il la fertilité ?\nPourquoi éviter les toxines environnementales ?\nQuel impact de l'âge sur la fertilité ?",
"url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Scleroderma,+Diffuse&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Fécondostimulants",
"description": "Quels sont les principaux fécondostimulants ?\nComment fonctionne le clomifène ?\nQuand utiliser des gonadotrophines ?\nQuels effets secondaires des fécondostimulants ?\nComment se déroule une stimulation ovarienne ?",
"url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Scleroderma,+Diffuse&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Fécondostimulants",
"description": "Quelles complications des fécondostimulants ?\nComment reconnaître le syndrome d'hyperstimulation ?\nQuels risques de grossesses multiples ?\nQuelles sont les conséquences d'une grossesse multiple ?\nQuels effets à long terme des fécondostimulants ?",
"url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Scleroderma,+Diffuse&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Fécondostimulants",
"description": "Quels facteurs de risque d'infertilité ?\nQuel impact des antécédents familiaux ?\nComment le poids influence-t-il la fertilité ?\nQuel rôle des maladies chroniques ?\nComment l'environnement influence-t-il la fertilité ?",
"url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Scleroderma,+Diffuse&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'infertilité ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'infertilité se diagnostique par des tests hormonaux, échographies et analyses de sperme."
}
},
{
"@type": "Question",
"name": "Quels tests pour évaluer la réserve ovarienne ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par la mesure de l'hormone antimüllérienne (AMH) et l'échographie."
}
},
{
"@type": "Question",
"name": "Quand consulter un spécialiste de la fertilité ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est conseillé de consulter après un an d'essais infructueux pour les couples de moins de 35 ans."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent un problème d'ovulation ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des cycles irréguliers, des règles absentes ou des douleurs pelviennes peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Comment évaluer la qualité du sperme ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La qualité du sperme est évaluée par une analyse de sperme, mesurant la concentration et la motilité."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'infertilité chez la femme ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des cycles irréguliers, des douleurs pelviennes et des règles absentes."
}
},
{
"@type": "Question",
"name": "Quels signes d'infertilité chez l'homme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes peuvent inclure des problèmes d'érection, des douleurs testiculaires ou des anomalies du sperme."
}
},
{
"@type": "Question",
"name": "Comment reconnaître un déséquilibre hormonal ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme l'acné, la prise de poids ou des changements d'humeur peuvent indiquer un déséquilibre."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'ovulation irrégulière ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des cycles menstruels irréguliers et des douleurs pelviennes peuvent signaler une ovulation irrégulière."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une maladie des ovaires ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs pelviennes, des règles irrégulières et des problèmes de fertilité."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'infertilité ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un poids santé, éviter le tabac et gérer le stress peuvent aider à prévenir l'infertilité."
}
},
{
"@type": "Question",
"name": "Quel rôle de l'alimentation sur la fertilité ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée riche en antioxydants et en acides gras oméga-3 peut améliorer la fertilité."
}
},
{
"@type": "Question",
"name": "Comment le stress affecte-t-il la fertilité ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut perturber les cycles hormonaux et affecter l'ovulation, réduisant ainsi la fertilité."
}
},
{
"@type": "Question",
"name": "Pourquoi éviter les toxines environnementales ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les toxines peuvent nuire à la qualité du sperme et à la santé reproductive, augmentant le risque d'infertilité."
}
},
{
"@type": "Question",
"name": "Quel impact de l'âge sur la fertilité ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé réduit la qualité des ovules et la fertilité, surtout après 35 ans chez les femmes."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux fécondostimulants ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux fécondostimulants incluent le clomifène, les gonadotrophines et l'acide folique."
}
},
{
"@type": "Question",
"name": "Comment fonctionne le clomifène ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le clomifène stimule l'ovulation en bloquant les récepteurs d'œstrogènes dans l'hypothalamus."
}
},
{
"@type": "Question",
"name": "Quand utiliser des gonadotrophines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les gonadotrophines sont utilisées lorsque le clomifène est inefficace ou en cas d'infertilité sévère."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires des fécondostimulants ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des bouffées de chaleur, des nausées et des douleurs abdominales."
}
},
{
"@type": "Question",
"name": "Comment se déroule une stimulation ovarienne ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La stimulation ovarienne implique des injections de médicaments et un suivi échographique régulier."
}
},
{
"@type": "Question",
"name": "Quelles complications des fécondostimulants ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent inclure le syndrome d'hyperstimulation ovarienne et des grossesses multiples."
}
},
{
"@type": "Question",
"name": "Comment reconnaître le syndrome d'hyperstimulation ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs abdominales, des nausées et un gain de poids rapide après traitement."
}
},
{
"@type": "Question",
"name": "Quels risques de grossesses multiples ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les fécondostimulants augmentent le risque de grossesses multiples, ce qui peut entraîner des complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'une grossesse multiple ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les grossesses multiples peuvent entraîner des naissances prématurées et des complications pour la mère."
}
},
{
"@type": "Question",
"name": "Quels effets à long terme des fécondostimulants ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets à long terme peuvent inclure des risques accrus de cancer ovarien, bien que les données soient limitées."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque d'infertilité ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, des antécédents médicaux, le tabagisme et l'obésité."
}
},
{
"@type": "Question",
"name": "Quel impact des antécédents familiaux ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux d'infertilité peuvent augmenter le risque d'infertilité chez les individus."
}
},
{
"@type": "Question",
"name": "Comment le poids influence-t-il la fertilité ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un poids excessif ou insuffisant peut perturber les cycles hormonaux et affecter la fertilité."
}
},
{
"@type": "Question",
"name": "Quel rôle des maladies chroniques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des maladies comme le diabète ou le syndrome des ovaires polykystiques peuvent affecter la fertilité."
}
},
{
"@type": "Question",
"name": "Comment l'environnement influence-t-il la fertilité ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'exposition à des produits chimiques et à des toxines peut nuire à la qualité reproductive."
}
}
]
}
]
}
Patients with diffuse cutaneous systemic sclerosis (dcSSc) frequently show spontaneous improvement of skin fibrosis. Our aim was to examine whether an improvement in skin fibrosis predicts lower likel...
Patients from the European Scleroderma Trials and Research (EUSTAR) cohort with dcSSc, baseline modified Rodnan skin score (mRSS) ≥7, and valid mRSS at 12±3 months follow up were included. Regression/...
Of 1257 included patients, 883 (70.2%) were stable, 282 (22.4%) regressive, and 92 (7.3%) progressive. Regressive patients, adjusted for baseline mRSS, baseline immunosuppression, baseline FVC, and di...
We found that regression of skin fibrosis is associated with a lower probability of lung progression and better survival at follow up. The link between the disease course of skin and lung fibrosis in ...
This phase 3 study was undertaken to investigate the efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in patients with diffuse cutaneous systemic sclerosis (dcSSc)....
A multinational double-blind study was conducted in 365 dcSSc patients who were randomized and dosed 1:1:1 with lenabasum 20 mg, lenabasum 5 mg, or placebo, each twice daily and added to background tr...
The primary end point, the American College of Rheumatology combined response index in dcSSc (CRISS) at week 52 for lenabasum 20 mg twice a day versus placebo, was not met, with CRISS score of 0.888 v...
A benefit of lenabasum in dcSSc was not demonstrated. Most patients were treated with background IST, and treatment with mycophenolate mofetil in particular was associated with better outcomes. These ...
We undertook this study to explore the efficacy, safety, and tolerability of ziritaxestat, a selective autotaxin inhibitor, in patients with early diffuse cutaneous systemic sclerosis (dcSSc)....
NOVESA was a 24-week, multicenter, phase IIa, double-blind, placebo-controlled study. Adults with dcSSc were randomized to oral ziritaxestat 600 mg once daily or matching placebo. The primary efficacy...
Patients were randomized to ziritaxestat (n = 21) or placebo (n = 12). Reduction in MRSS was significantly greater in the ziritaxestat group versus the placebo group (-8.9 versus -6.0 units, respectiv...
Ziritaxestat resulted in significantly greater reduction in MRSS at week 24 than placebo; no new safety signals emerged. Biomarker analysis suggests ziritaxestat may reduce fibrosis. Modulation of the...
Autoantibody production is a hallmark of systemic sclerosis (SSc) and the most extensively studied role of B cells in the pathogenesis of the disease. However, the potential involvement of innate immu...
We report a rare case of Purtscher-like retinopathy related to systemic sclerosis, presented unprecedently an ultra-widefield optical coherence tomography angiography image for this combination, and s...
Keloidal scleroderma is a variant of scleroderma that presents as firm keloidal nodules or plaques. Due to the similarity in morphology and pathology, it is often distinguished from a hypertrophic sca...
Scleroderma is a systemic inflammatory disorder that can compromise the gastrointestinal tract in up to 90% of patients....
The purpose of this work is to characterize esophageal, gastric, and intestinal compromise in patients with scleroderma by means of minimally invasive methods and its association with symptoms and sev...
Patients with systemic sclerosis were recruited according to the criteria of the American College of Rheumatology. The study of digestive involvement was carried out on four consecutive days: esophage...
A total of 30 patients were included, with an average age of 52.7 years and 93% women. Average disease evolution duration was 6.5 years, 70% with limited variety. Rodnan averaged 12 points, being high...
Gastrointestinal involvement in patients with scleroderma is frequent and is observed regardless of the symptoms and clinical characteristics of the latter, except for skin involvement....
Systemic sclerosis is a systemic connective tissue disease whose main pathophysiological mechanism is a progressive fibrosis of internal organs and skin leading to thickening and induration. Blood ves...
[This corrects the article DOI: 10.3389/fimmu.2024.1351675.]....
Immune checkpoint inhibitors (ICI) are the standard of care for various malignancies and have been associated with a wide spectrum of complications that are phenotypically akin to primary autoimmune d...